All News

This week’s podcast covers psoriasis trial results, intranasal insulin, COVID-19 booster safety, GLP-1 use in diabetes, and RSV vaccine uptake.

A secondary analysis of the DANFLU-2 trial found adults ≥65 receiving a high-dose flu vaccine had a 46% lower risk of myocarditis or pericarditis compared with standard-dose vaccination.

Your daily dose of the clinical news you may have missed.

With the surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.

Research reveals that older age and lower aerobic fitness significantly increase the risk of arrhythmias, highlighting the need for early screening and fitness maintenance.

Your daily dose of the clinical news you may have missed.

Obesity medicine specialist Michael Crotty, MD, discusses the benefits of GLP-1 receptor agonist use in weight management and its impact on obesity-related comorbidities.

FDA clears MiniMed 780G for integration with Abbott’s Instinct sensor and approves its use in insulin-requiring T2D, expanding automated insulin delivery options.

Your daily dose of the clinical news you may have missed.

Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers.

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.

The FDA has accepted a New Drug Application for ensitrelvir, with a PDUFA action date set for June 16, 2026.

Your daily dose of the clinical news you may have missed.

The FDA has cleared Eisai and Biogen’s Leqembi Iqlik, the first at-home subcutaneous autoinjector for maintenance therapy in patients with early Alzheimer disease.

Your daily dose of the clinical news you may have missed.

Primary care clinicians see a higher share of visits for depression than mental health professionals largely because they know their patients so well, Lovins said.

Based on the FAQ section in the ACC's 2025 Concise Clinical Guidance on vaccination in adults with CVD, this short slideshow also offers recommended answers.

Teva announced approval of the generic formulation of Saxenda, which could help expand access to the extremely popular class of antiobesity medications.